RxDoctor Payments Data

Ofer Levy

Pediatric Infectious Diseases · Boston, MANPI 1316034663

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $30,030 of the $41,197 with a category attached, or 72.9%. 7 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.0% of the total. Reporting peaked in 2023 at $19,119 and has fallen 86.4% since, to $2,600 in 2025.

$41,197in general payments, 2019–2025

Across 32 payments — averaging $1287.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$14K
  • GSK$8K
  • UCB SA$7K
  • Pfizer$6K
  • Merck$3K
  • Sanofi US Services Inc.$2K
  • plus $2K from 1 others
$1,934,021in research payments, 2019–2025

Across 18 payments — averaging $107,446 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1.6M
  • Pfizer$320K
  • Sanofi Pasteur Inc.$2K

What the payments were for

  • Consulting fees$30,03073%
  • Speaking & faculty fees$3,0007%
  • Travel & lodging$8,03219%
  • Food & beverage$1350%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.1$13,598
GSK22$8,245
UCB SA1$6,840
Pfizer5$5,522
Merck1$3,400
Sanofi US Services Inc.1$2,000
AstraZeneca1$1,593

How this compares

$41,197 in reported general payments places this provider in the 85th percentile of 29 pediatric infectious diseases providers in Massachusetts.

See all pediatric infectious diseases providers in Massachusetts

Other pediatric infectious diseases in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →